RxDoctor Payments Data

Michelle Whipple, PA

Physician Assistant · San Diego, CANPI 1992080691

Payments from drug & device makers

$1,333in general payments, 2019–2025

Across 80 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$788
  • Johnson & Johnson$234
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$153
  • E.r. Squibb & Sons, L.L.C.$57
  • Otsuka America Pharmaceutical, Inc.$41
  • Teva Pharmaceuticals USA, Inc.$31
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$1,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,333 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$26,877
Medicare patients
35
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate193$638,929
IngrezzaValbenazine Tosylate80$307,559
LybalviOlanzapine/Samidorphan Malate31$48,359
FanaptIloperidone13$46,710
Abilify MaintenaAripiprazole16$42,128
CaplytaLumateperone Tosylate11$18,911
Paliperidone ErPaliperidone17$11,937
Clozapine164$9,915
Olanzapine332$8,652
Divalproex Sodium ErDivalproex Sodium80$7,828
Chlorpromazine Hcl24$6,388
Fluphenazine Hcl110$5,112
Lurasidone Hcl38$4,600
Olanzapine OdtOlanzapine100$4,372
Haloperidol Decanoate100$3,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$234$638,929193 claims
Alkermes, Inc.Lybalvi$788$48,35931 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$41$42,12816 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$153$18,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →